GE HealthCare Technologies Inc.

Service contracts, contrast-media repurchases, and SaaS subscriptions made up roughly 45% of FY2025 revenue, and the $21.8 billion backlog (up $2 billion year over year) combined with a book-to-bill ratio of 1.07x on a trailing twelve-month basis as of year-end 2025 provides meaningful near-term visibility. The 45% recurring base falls short of the 70%-plus level needed for the highest predictability, and equipment-order timing remains sensitive to hospital budget cycles.

Four segments (Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics) address genuinely different hospital workflows, from capital imaging equipment to consumable contrast agents supporting 130 million procedures annually. Imaging and AVS together account for the majority of equipment revenue, so single-modality softness creates disproportionate top-line pressure.

FY2025 revenue was split roughly 44% U.S., 10% China, and 46% rest-of-world, with no single country above half of sales. The U.S. share exceeds the level needed for the strongest diversification, and China at 10% is a material concentration given the ongoing anti-corruption headwinds that drove a $104 million revenue decline in FY2025.

Service and PDx businesses carry higher incremental margins than hardware, providing some operating leverage as the installed base grows, but capital equipment manufacturing and PDx production facilities require ongoing capital investment. The mix of recurring-margin businesses and capital-intensive equipment production constrains the overall operating leverage profile.

Medical imaging systems and contrast agents are mission-critical to hospital workflows, and multi-year service contracts make a large share of revenue defensive through budget cycles. The capital-equipment portion of revenue (the majority of non-service sales) is more discretionary and tends to be deferred in hospital CapEx freezes, limiting overall quality to an above-average rather than superior level.